<DOC>
	<DOC>NCT01325337</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.</brief_summary>
	<brief_title>Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<criteria>Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Willingness to have microdottattoo applied to scalp Willingness to maintain same hair style, length and hair color during study Drug or alcohol abuse within 12 months HIV positive Received hair transplants or had scalp reductions Use of hair weaves, hair extensions or wigs within 3 months Oral or topical minoxidil treatment within 6 months Application of topical steroids or nonsteroidal antiinflammatory drugs (NSAIDs) to scalp within 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>